# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Kostas Biliouris downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Market Perform and raises th...
Piper Sandler analyst Yasmeen Rahimi downgrades Tourmaline Bio (NASDAQ:TRML) from Overweight to Neutral and lowers the price...
Truist Securities analyst Robyn Karnauskas downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Hold and lowers the price tar...
Guggenheim analyst Yatin Suneja downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price target from...
HC Wainwright & Co. analyst Yi Chen downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price tar...
Chardan Capital analyst Daniil Gataulin downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price tar...
LifeSci Capital analyst Rami Katkhuda downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Market Perform and announce...
Jefferies analyst Roger Song downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Hold and lowers the price target from $64 t...